Esophageal Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | BeiGene, Amgen, Oncolys, Pfizer, Novartis, TESARO

Esophageal Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | BeiGene, Amgen, Oncolys, Pfizer, Novartis, TESARO
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Esophageal Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Esophageal Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Esophageal Cancer Market. 

The Esophageal Cancer Pipeline report embraces in-depth commercial, regulatory, and Esophageal Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Esophageal Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Esophageal Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Esophageal Cancer treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Esophageal Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Esophageal Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Esophageal Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Esophageal Cancer therapeutic market.

Esophageal Cancer Therapeutics Landscape

Treatment of esophageal cancer depends on many factors, including the stages of cancer. A patient with stage 0 esophageal cancer may have surgery, photodynamic therapy, radiofrequency ablation, or endoscopic mucosal resection. A patient with stage I, II, and III esophageal cancer may have surgery, chemotherapy, or radiation. Whereas, a patient with stage IV esophageal cancer may have Chemotherapy, radiation, targeted therapy, or immunotherapy; treatment for this stage focuses on “palliative” therapy.

Targeted therapies include drugs like trastuzumab (Herceptin, OGIVRI) which may be used along with chemotherapy as a first treatment for metastatic esophageal adenocarcinoma. Trastuzumab deruxtecan (ENHERTU) is also approved as the first treatment for metastatic esophageal adenocarcinoma. Ramucirumab (CYRAMZA) is recommended as a treatment option in combination with paclitaxel chemotherapy for advanced gastroesophageal or gastroesophageal junction adenocarcinoma if first-line therapy has not worked. Further immunotherapies include Pembrolizumab (KEYTRUDA) and Nivolumab (OPDIVO); checkpoint inhibitors target the PD-1/PD-L1 pathway.

Currently, six drugs are approved for the treatment of esophageal cancer. To further improve the treatment outlook, there are approx. 80+ key companies developing therapies for Esophageal Cancer. Currently, Seagen is leading the therapeutics market with its Esophageal Cancer drug candidates in the most advanced stage of clinical development.

Esophageal Cancer Companies Actively Working in the Therapeutic Market Include:

BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc, Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc.,, Adlai Nortye, Seagen, and others.

Emerging and Marketed Esophageal Cancer Drugs Covered in the Report Include:

  • AN-0025: Adlai Nortye

  • Tucatinib: Seagen

  • APX 005M: Apexigen

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Esophageal Cancer Companies Working in the Market @

Analysis of Emerging Esophageal Cancer Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Learn How the Esophageal Cancer Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Esophageal Cancer Treatment Patterns

4. Esophageal Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Esophageal Cancer Late Stage Products (Phase-III)

7. Esophageal Cancer Mid-Stage Products (Phase-II)

8. Esophageal Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Esophageal Cancer Discontinued Products

13. Esophageal Cancer Product Profiles

14. Major Esophageal Cancer Companies in the Market

15. Key Products in the Esophageal Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Esophageal Cancer Unmet Needs

18. Esophageal Cancer Future Perspectives

19. Esophageal Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight 

Castration-Resistant Prostate Cancer (CRPC) Market

“Castration-Resistant Prostate Cancer (CRPC) Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Castration-Resistant Prostate Cancer market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Castration-Resistant Prostate Cancer market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States